Promoter methylation assay of SASH1 gene in breast cancer

Journal of B.U.ON.

Volumn 18, Issue 4, 2013, Pages 891-898

  Lin, Sheyu ^a,c   Liu, Hui ^b   Zhang, Junyu ^a   Xu, Jiawei ^a   Wang, Honglian ^a   Sang, Qing ^a   Zhang, Hengwei ^b   Guo, Xuhui ^b   Xing, Qinghe ^a   He, Lin ^a  

^a FUDAN UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c NANTONG UNIVERSITY   (China)

Author keywords

Breast cancer; Dna methylation; SASH1; Tumor suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA;

ARTICLE; BREAST CANCER; CANCER TISSUE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SASH1 GENE; UPREGULATION;

AZACITIDINE; BREAST NEOPLASMS; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84893152838     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-1426.
2. Jousilahti P, Salomaa V, Kuulasmaa K, Niemela M, Vartiainen E. Total and cause specific mortality among participants and non-participants of population based health surveys:a comprehensive follow up of 54 372 Finnish men and women. J Epidemiol Commun Health 2005;59:310-315. (Pubitemid 40460584)
3. Gray L, Batty GD, Craig P et al. Cohort profile:the Scottish health surveys cohort:linkage of study participants to routinely collected records for mortality, hospital discharge, cancer and offspring birth characteristics in three nationwide studies. Int J Epidemiol 2010;39:345-350.
4. Veeck J, Niederacher D, An H et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 2006;25:3479-3488. (Pubitemid 43877051)
5. Beaumont T, Leadbeater M. Treatment and care of patients with metastatic breast cancer. Nurs Stand 2011;25:49-56.
6. Dai C, Gu W. p53 post-translational modification:-deregulated in tumorigenesis. Trends Mol Med 2010;16:528-536.
7. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-1013. (Pubitemid 34160279)
8. Zhang Y, Pan Y, Zheng L et al. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 2011;71:3257-3267.
9. Zhao Y, Kong X, Li X et al. Metadherin mediates lipopolysaccharide- induced migration and invasion of breast cancer cells. PloS one 2011;6:e29363.
10. Narayan G, Freddy AJ, Xie D et al. Promoter methylation-mediated inactivation of PCDH10 in acute lymphoblastic leukemia contributes to chemotherapy resistance. Genes Chromosomes Cancer 2011;50:1043-1053.
11. Zeller C, Hinzmann B, Seitz S et al. SASH 1:a candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer. Oncogene 2003;22:2972-2983. (Pubitemid 36648925)
12. Lee EY, Muller WJ. Oncogenes and tumor suppressor genes. Cold Spring Harbor, Perspectives in Biology 2010;2:a003236.
13. Hesson LB, Dunwell TL, Cooper WN et al. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer 2009;8:1-10.
14. Rimkus R, Martini M, Friederichs J et al. Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br J Cancer 2006;95:1419-1423. (Pubitemid 44760096)
15. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer:how cellular identity goes awry. Develop Cell 2010;19:698-711.
16. Goeppert B, Schmezer P, Dutruel C et al. Down-regulation of tumor suppressor A kinase anchor protein 12 in human hepatocarcinogenesis by epigenetic mechanisms. Hepatology 2010;52:2023-2033.
17. Banerjee D, Nandagopal K. Potential interaction between the GARS-AIRS-GART gene and CP2/LBP-lc/ LSF transcription factor in Down syndrome-related Alzheimer disease. Cell Mol Neurobiol 2007;27:1117-1126. (Pubitemid 351170077)
18. Dong S, Ying S, Kojima T et al. Crucial roles of MZF1 and Spl in the transcriptional regulation of the pepti-dylarginine deiminase type I gene (PADI1) in human keratinocytes. J Investig Dermatol 2008;128:549-557. (Pubitemid 351252655)
19. Luo X, Zhang X, Shao W, Yin Y, Zhou J. Crucial roles of MZF-1 in the transcriptional regulation of apomor-phine-induced modulation of FGF-2 expression in astrocytic cultures. J Neurochem 2009;108:952-961.
20. Wasylyk B, Hagman J, Gutierrez-Hartmann A. Ets transcription factors:nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem Sci 1998;23:213-216. (Pubitemid 28302618)
21. Convertini P, Infantino V, Bisaccia F, Palmieri F, Iacobazzi V. Role of FOXA and Spl in mitochondrial acylcamitine carrier gene expression in different cell lines. Biochem Biophys Res Commun 2011;404:376-381.
22. Kim HL, Ko MS, Kim HK et al. Transcription factor Spl regulates basal transcription of the human DRG2 gene. Biochim Biophys Acta 2011;1809:184-190.
23. Gao SY, Li EM, Cui L et al. Spl and AP-1 regulate expression of the human gene VIL2 in esophageal carcinoma cells. J Biol Chem 2009;284:7995-8004.